Tedatioxetine

Tedatioxetine (pronounced te-da-ti-ox-e-tine) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that was under development by Lundbeck and Takeda Pharmaceutical Company for the treatment of major depressive disorder and generalized anxiety disorder.

Etymology

The name "Tedatioxetine" is derived from the combination of chemical elements present in the drug. The prefix "Ted" is derived from Takeda Pharmaceutical Company, the co-developer of the drug. The suffix "ioxetine" is common in drugs that act as reuptake inhibitors, indicating its function.

Pharmacology

Tedatioxetine acts as a reuptake inhibitor, preventing the reabsorption of certain neurotransmitters in the brain. It specifically inhibits the reuptake of serotonin, norepinephrine, and dopamine, which are chemicals that transmit signals in the brain and help regulate mood.

Clinical Trials

In clinical trials, Tedatioxetine was found to be effective in the treatment of major depressive disorder and generalized anxiety disorder. However, the development of the drug was discontinued in 2016 due to unsatisfactory results in late-stage clinical trials.